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1. Abstract 
 
 
An E2F associated phospho protein (EAPP) has been recently identified through 
yeast two-hybrid assay. EAPP consists of 285 amino acids, weighs about 40 KDa, is 
localized in the cell nucleus and interacts with a subgroup of E2F proteins. EAPP is 
involved in cell cycle regulation as it significantly stimulates the S-phase entry of the 
cell and disappears in M phase. EAPP can control E2F-mediated transcription and 
affect cell proliferation. 
In this study the interactions and post-translational modifications of EAPP have been 
investigated. Different truncations of this protein were examined for activity and post-
translational modifications, among that sumoylation and acetylation, to figure out the 
functional domains and regulation of EAPP. Besides, the stability of the protein and 
the domain affecting this character were also studied. 
Treatment with TSA, an HDAC inhibitor, induced acetylation of EAPP at its N 
terminus, within amino acids 1-140. 
Through FACS method it was shown that the cells expressing truncated EAPP 1-140, 
took much longer to re-enter the cell cycle after the release from Nocodazole which 
arrests the cells at M phase. It in turn shows the possibility of involvement of this 
truncation in inhibition of cyclin-dependent kinase (CDK) complexes which control the 
transitions between different phases of the cell cycle. 
Utilizing Pulse Chase methods and treating the cells expressing full length or 
truncated versions of EAPP it was demonstrated that the amino-terminal part of 
EAPP confers acetylation-dependent stability to the protein.  
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1. Zusammenfassung 
 
Das E2F assoziierte Phosphoprotein (EAPP) wurde kürzlich in einem Two-Hybrid-
Versuch in Hefe identifiziert. Das ca. 40 kDa große EAPP besteht aus 285 
Aminosäuren, ist im Zellkern lokalisiert und interagiert mit einer Untergruppe von 
E2F-Proteinen. EAPP stimuliert in der Zelle maßgeblich den Übergang von G1- zu S-
Phase und verschwindet in der M-Phase. Somit spielt EAPP eine Rolle in der 
Zellzyklus-Regulation, kontrolliert aber auch E2F-vermittelte Transkription und 
beeinflusst die Zellteilung. 
Thema dieser Arbeit ist EAPP und seine Interaktionen und Modifikationen nach der 
Translation. Hierzu wurden verschiedene Verkürzungen von EAPP auf Aktivität und 
Modifikationen wie Sumoylierung und Acetylierung untersucht, um mehr über die 
funktionellen Proteindomänen und ihre Regulation herauszufinden. Weiters wurden 
EAPP-Domänen hinsichtlich ihres Einflusses auf die Proteinstabilität untersucht. 
Behandlung mit TSA (einem HDAC-Hemmstoff) induzierte Acetylierung am N-
terminalen Teil der EAPP-Verkürzung 1-140. Mittels FACS-Analyse konnte gezeigt 
werden, dass Zellen, welche die EAPP-Verkürzung 1-140 exprimieren, sehr viel 
länger brauchen, um nach einer Behandlung mit Nocodazole (arretiert Zellen in M-
Phase) eine neue Zellzyklusrunde zu starten. Diese Ergebnisse lassen darauf 
schließen, dass diese EAPP-Domäne an der Inhibierung von Cyclin-abhängigen 
Kinase (CDK)-Komplexen beteiligt ist, welche die Übergänge in die verschiedenen 
Zellzyklus-Phasen kontrollieren. 
Mittels Pulse Chase-Versuchen und Cycloheximid-Behandlung von Zellen, welche 
die EAPP-Verkürzung 1-140 exprimieren, konnte gezeigt werden, dass EAPP an 
seinem N-terminalen Ende (Verkürzung 1-140) sehr viel stabiler ist. Die Quintessenz 
dieser Arbeit besagt, dass die Acetylierung von EAPP an seinem N-terminalen Ende  
seine Stabilität beeinflusst. 
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 2. INTRODUCTION 
 
2.1 The mammalian cell cycle  
The cell cycle is a complex ordered set of events that control the cell division. The 
activation of two significant proteins; cyclins and cyclin dependent kinases (cdks) 
regulate the progression of the cell cycle. The cell cycle consists of four different 
phases, G1-, S-, G2-phase and Mitosis. The phosphorylation of numerous proteins 
caused by different sets of cdk- cyclin complexes leads to the entry of the cell into 
mitosis. There is an additional state of the cell, the G0-phase, which allows the cell to 
rest for a period of time, before going through the new cell cycle or terminal 
differentiation. 
 
2.2 The E2F family of transcription factors 
E2F play a crucial role in a wide range of biological processes, comprising DNA 
replication, mitosis, the mitotic checkpoint, DNA-damage checkpoints, DNA repair, 
differentiation, development and apoptosis (Polager et al., 2008). It can also 
function as transcriptional repressor or activator (De Gregori et al. 2006). The 
identification of E2F family of proteins was based on its role in advancing the G0 to 
S phase transition (Blais et al. 2007). E2F activity will be deregulated through many 
different mechanisms in the vast majority of human tumors. These comprise 
functional loss of the pocket protein family including the retinoblastoma protein 
(pRB); phosphorylation of pRB promoted by amplification of cyclin D; loss of p16 a 
cyclin-dependent kinase inhibitor that inhibits the phosphorylation of pRB (Polager 
et al., 2008). E2F transcription factors may thus play a significant role in regulating 
the transcription of different cellular processes far beyond the originally described 
cell cycle and proliferation (Rotheneder et al., 2007).  
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The E2F family comprises eight different genes (E2F1-8) in mammals, which code 
for nine distinct proteins (Polager et al., 2008 ; De Gregori et al., 2006). All members 
of this transcription factors contain a DNA-binding domain. E2F1–5 have a 
transactivation domain which enables the activation of gene expression. Additionally 
E2F1–6 comprise a dimerization domain which is necessary for their interaction with 
a member of the dimerization-partner family (DP1–DP4). This interaction enables 
them to bind DNA and function as transcriptional regulators. E2F1, E2F2 and 
E2F3a, are named “activator E2fs’” they are believed to function mostly in gene 
expression activation and they interact only with pRB. E2F3b, E2F4 and 5, on the 
other hand, are repressors and are believed to be capable of interacting with the 
other pocket proteins. The main role of E2F6–8 is repression of gene expression, 
they do not have any interaction with pocket proteins and are mostly regarded as the 
‘repressor E2Fs’ (Polager et al., 2008; Alonso MM et al., 2008). 
E2F-1, -2, and –3 can function as oncogene products (Xu etal., 1995), and E2F-1 is 
also known for its role as a tumor suppressor (Field et al., 1996; Yamasaki et al., 
1996). This can be described by the capability of E2F-1 in inducing apoptosis, for 
instance by activating the expression of the tumor suppressor protein p14ARF 
(Bates et al., 1998). 
E2F1 can either induce cell proliferation or cell death. Signal from DNA damage can 
lead E2F1 to apoptosis through p53-dependent and p53-independent pathways, 
(Rotheneder et al., 2007) whereas signal-transduction pathways, such as the 
phosphatidylinositol 3 kinase (PI3K)–protein kinase B (Akt) and epidermal-growth-
factor receptor (EGFR)–ras pathways play a role in inhibition of E2F-induced 
apoptosis (Polager et al., 2008). 
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Upstream signals direct E2F1 to proliferation or apoptosis. Mitogenic signals and DNA 
damage activate different signaling pathways that determine whether E2F1 activity will 
induce transcription of proliferative or apoptotic genes. Mitogenic stimuli elevate cyclin-D 
levels, leading to repression of pRB activity via phosphorylation by cyclin D–CDK4 or cyclin 
D–CDK6 complexes. Subsequently, E2F1 is free to activate proliferative or apoptotic genes. 
When mitogenic signals also switch on the PI3K–Akt pathway or, in some situations EGFR–
Ras–Raf signaling, the apoptotic activity of E2F1 is inhibited and it induces mainly 
proliferation. In response to DNA damage, signals direct E2F1 to activate its apoptotic target 
genes: pRB acetylation specifically releases E2F1, and not other E2Fs, to enable induction 
of apoptosis; E2F1 is phosphorylated by ATM and Chk2 and also acetylated these 
modifications direct it preferentially to its apoptotic target genes. In addition, binding of Jab1, 
an E2F pro-apoptotic co-factor, enhances the apoptotic activity of E2F1. Conversely, SirT1 
is induced after DNA damage and it can inhibit the apoptotic functions of E2F1 (Polager et 
al. 2008). 
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  2.2.1 The role of p53 in E2F1-induced apoptosis 
Accumulation of p53 is induced by ectopic expression of E2F1 (Kowalik et al., 
1995; Hiebert et al., 1995) and direct transactivation of p14ARFtumor suppressor 
gene by E2F1 is one mechanism underlying this phenomenon (Bates et al 1998; 
Robertson et al., 1998). ARF has an interaction with the Mdm2 E3 ubiquitin ligase 
and inhibits the ability of Mdm2 to target p53 for ubiquitination and subsequent 
degradation (Weber et al., 1999). Therefore, Increase in ARF levels induced by 
E2F1, leads to activation and stabilization of p53 (Ginsberg et al., 2002). 
Additionally, there are also ARF-independent functional links between E2F1 and 
p53 whereby E2F1 can increase p53 levels and p53-dependent apoptosis also in 
the absence of ARF. Recently a number of studies show that E2F1 over-expression 
or pRB inactivation leads to apoptosis that is inhibited by loss of p53 but not by loss 
of ARF (Russel et al., 2002; Tolbert et al., 2002; Tsai et al., 2002). E2F1 has an 
interaction with p53 via the cyclin A binding domain of E2F1 and this interaction 
increases the apoptotic activity of p53 (Hsieh et al., 2002). This function of E2F1 is 
shared by E2F2 and E2F3 (Ginsberg et al., 2002; Hsieh et al., 2002). 
2.2.2 E2F1 sensitizes cells to apoptotic stimuli 
In a variety of cell types over-expression of E2F1 followed by treatment with 
ionizing radiation or chemotherapeutic drugs such as the topoisomerase II 
inhibitors, etoposide and adriamycin sensitizes cells to apoptosis (Nip et al., 1997; 
Pruschy et al., 1999). This increased level of E2F1 protein is due to protein 
stabilization which is mediated by an ATM-induced phosphorylation (Lin W.C. et al., 
2001). Currently, the molecular mechanisms which underlie the capability of E2F1 
to sensitize cells to apoptotic stimuli are not completely understood. However, it is 
significantly established that the pRB pathway is functionally inactivated in most 
human cancers leading to deregulation of E2F activity. Thus the increased 
sensitivity of tumor cells to radio- and chemotherapy might be due to the capability 
of E2F to induce apoptosis in reaction to genotoxic stress (Ginsberg et al., 2002). 
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Pathways of E2F1 induced apoptosis (Ginsberg et.al.2002). 
  
2.3 E2F and the pocket protein family 
The gene regulation of E2F results from a complex mechanism which enables the 
cell cycle to enter S phase and begin DNA replication only under approving 
conditions. For example, if genomic DNA sustained damages and requires repair, cell 
cycle will not proceed to S phase and in this way the accumulation of genetic defects 
within the cellular genome might be prevented. In this context, the regulators of E2F 
activity are the members of Rb family, which are capable of binding to E2F and 
preventing it from interacting with the promoter region of those genes which are 
crucial for S phase entry (Sun et al., 2007). 
  
The pocket protein family consists of three members, pRb (pRb1/p105), p107 and 
p130 (pRb2). They are all nuclear proteins and operate mainly as regulators of the 
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cell cycle, although several studies presume that pocket proteins are also involved in 
development and differentiation (Lipinski and Jacks, 1999; Thomas et al., 2001).  
The retinoblastoma susceptibility gene was identified as the first tumour suppressor 
gene. pRB, The product of this gene, is known as the negative regulator of cell 
proliferation. Active pRB has interactions with many nuclear proteins including 
numerous transcription factors and chromatin associated proteins (Morris et al., 
2001; Goodrich et al., 2003 and 2006). The E2F transcription factors are the best-
known targets of pRB (Bandara et al., 1991; Chellapan et al., 1991; Chittenden et al., 
1991). Both pRB and pRB family members inhibit E2Fmediated activation and 
enhance E2F mediated repression. pRB family members are capable of repressing 
E2F dependent transcription and this mechanism is controlled by Cyclin -dependent 
kinases (CDKs) (van den Heuvel et al., 2008). 
The three pocket proteins show similarities especially in the A and B pocket but there 
are also obvious distinctions. p107 and p130 have much closer similarity to each 
other than either to pRB. The expression pattern of pocket proteins varies, p107 is 
highly expressed in cycling cells and p130 is expressed at higher levels in cells that 
have exited the cell cycle (Classon et al., 2002; Mcpherson D., 2008).  
In quiescent cells (G0) and cells in early G phase, pRb2/p130 is highly expressed 
(Cobrinik et al., 1993; Smith et al., 1996) it interacts mainly with E2F4 and to a less 
extent with E2F5 (Hijmans et al., 1995; Vairo et al., 1995; Sun et al., 2007). This 
complex first binds to the promoter regions of the genes required for S phase entry. 
pRb2/p130 and pRb/p107 mediate the transcriptional expression in G0 and early G1. 
In addition to that, there is another mechanism provided by pRB/p105, which 
represses the expression of genes inducing S phase entry. pRb/p105 is expressed at 
moderate and stable levels during the cell cycle in contrast to pRb2/p130 and pRb/ 
p107 (Buchkovich et al., 1989; Chen et al., 1989; Decaprio et al., 1989; Mihara et al., 
1989). 
Pocket proteins interfere with the E2F transactivtion domain and in this way can 
inhibit the E2F transactivation activity directly. They also build complexes with histone 
deacetylases, histone methyltransferases, histone demethylases, and other 
chromatin modulators, which act to confer a repressive chromatin state around E2F 
target genes (Mcpherson D., 2008). These chromatin-remodelling factors cause  
Histon deacetylation, which results in chromatin condensation, which is not 
permissive for transcriptional activity. Naturally this suppresses the expression of 
those genes that are needed for entering into S phase (Sun et al., 2007). It has been 
shown that pRB, besides controlling the transition from G1 to S phase, also regulates 
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ribosome biogenesis and in this way directly connects cell growth to cell proliferation. 
Genetic alteration involving the pathway leading to pRB inactivation, such as RB1 
mutation or deletion, INK4a mutation, deletion or gene silencing and cyclin D1 or 
Cdk4 overexpression, are observed regularely in human cancers (Sherr et al., 2002; 
Montanaro et al., 2008). 
 
2.4 EAPP, a novel E2F binding protein 
EAPP was verified as a novel E2F-binding protein by means of a yeast two-hybrid 
interaction system utilizing the N-terminal domain of E2F-1 as the bait. Due to the 
fact that this protein is highly phosphorylated, it was named EAPP (e2F-associated 
phosphoprotein). EAPP is localized in the cell nucleus and interacts with the E2F 
members 1-3, but not with E2F4. It was observed that EAPP is present during the cell 
cycle but vanishes during mitosis. An identical increase of cells in S phase was 
resulted when EAPP was over-expressed in U2OS cells, whereas knocking down of 
EAPP mediated by RNAi diminished the fraction of cells in S-phase. Coming to the 
conclusion, EAPP controls E2F-regulated transcription and stimulates cell 
proliferation (Novy et al, 2005). 
 
On some promoters (e.g murine thymidine kinase promoter) that have just one E2F 
binding site but an Sp-1 binding site in addition (Ogris et al 1993) (Sp-1 also works 
synergistically with E2F) the activation by only E2F-1 alone was not that strong but 
the synergistic effect of E2F-1 and EAPP was much stronger than with the artificial 
E2F-promoter (Novy et al, 2005). As for p14 promoter it was shown that E2F-1 over-
expression resulted in a strong activation, but contrary to all other examined E2F 
controlled promoters, a co-expression of EAPP caused a p14-repression, showing 
that EAPP can also be a transcriptional repressor (for p14 repression EAPP does not 
need to be mediated by E2F). 
It was also examined if EAPP levels change during the cell cycle. Surprisingly the 
only phase of fluctuation was identified in mitotic cells, where EAPP disappeared in 
mitosis, showing that EAPP in this phase might interfere with the completion of the 
cell cycle. The mechanism of the EAPP degradation is not yet known. In M/G1 EAPP 
reappeared. In all other phases throughout the cell cycle EAPP levels remained 
rather constant (Novy et al, 2005). 
EAPP might interfere with the degradation of E2F-1 via the proteasome pathway, as 
a slight increase of E2F-1 levels was found in cells transiently over-expressing EAPP 
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(Novy et al 2005).This could be a result of the repression of the p14 mediated E2F-1 
degradation and/or enhanced E2F-1 promoter activity. 
 
2.5 Histon acetylation 
Intracellular and external mutagens attack DNA constantly. Sites of DNA damage 
need to be identified precisely so that the DNA repair machinery can be assembled  
for the proper location. The recognition of damaged sites, recruitment of repair 
factors and assembly of repair “factories” is modulated by posttranslational 
modifications(PTMs) These PTMs comprise acetylation, phosphorylation, methylation 
ubiquitination and sumoylation (Aimee N. Lake et al., 2007).  
Histones are a family of nuclear proteins that have interactions with DNA. This 
interaction results in DNA being wrapped around a core of histone octamer in the 
nucleosome. Histon Acetyl Transferases (HATs) mediate the acetylation of histones 
on lysine residues, This important mechanism has a crucial role in regulation of 
chromatin remodelling and gene expression. Histone deacetylase (HDAC) inhibitors 
are the recent category of chemotherapeutic drugs which modulate gene expression 
by increasing  histone acetylation , and therefore resulting in chromatin relaxation 
and modified gene expression. In preclinical studies, it has been demonstrated that 
HDAC inhibitors have strong anticancer activities (Rasheed at al. 2007). 
Hyperacetylation of histones  leads to an open modification of chromatin structure 
and influences transcription of the gene through accessibility of DNA to the basal 
transcription initiation machinery (Ogryzko et al., 1996; Grünstein et al., 1997; Struhl 
et al., 1998 and  Pons et al., 2009 ). 
 
 
2.5.1 Chromatin modification in response to DNA double strand 
break 
 
Chromatin makes a natural barrier against access to DNA throughout recombination, 
transcription and damage repair. Subsequent to DNA damage, chromatin structure is 
modified by (i) covalent histone modifications, (ii) ATP-dependent chromatin 
remodeling and (iii) incorporation of histone variants into nucleosomes (Vaquero et 
al., 2003; Shogren-Knaak et al., 2006). 
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One target of the ATM kinase subsequent to DNA damage is the histone H2A-variant 
H2AX (Redon et al., 2002). Histone H2AX is the major isoform in yeast and a minor 
H2A species in mammals. It is phosphorylated at the carboxy-terminal serine 139 in 
somatic cells in response to damage resulting from double strand breaks (DSBs) 
(Rogakou et al., 1998) 
Within minutes of damage Phosphorylated H2AX ( -H2AX) appears over large 
adjacent chromatin regions over tens of kilobase in yeast and up to 2 Mb in 
mammalian cells (Rogakou et al., 1999; Pandita et al., 2009). 
 
2.5.2 The role of HDAC inhibitors 
 
HDAC inhibitors, based on their structures, can be divided into four groups (Miller et 
al., 2003; Marks et al., 2004), comprising hydroximates, cyclic peptides, aliphatic 
acids and benzamides. The first discovered natural product belonging to 
hydroximates group was Trichostatin A (TSA) (Yoshida et al., 1990). Low 
concentration (nM) of TSA can result in cell differentiation and inhibit growth in 
tumors, with a tiny influence on normal cells (Marks et al., 2005). TSA causes cell 
cycle arrest or apoptosis by delaying the transition of G1/S phase (Mukhopadhyay et 
al., 2006). Despite the existence of strong evidence that TSA, as a common HDAC 
inhibitor, has a wide range of anti-cancer effects; it has not so far been used in the 
clinical trials, possibly because of its unrecognized  potential side effects (Pan et al., 
2007). 
Histone deacetylase (HDAC) inhibitors have been employed over the last decade as 
an anti-proliferative strategy targeting solid or hematopoietic malignant disorders 
(Kelly et al., 2005). 
Histone deacetylase (HDAC) inhibitors have been used as an anti-proliferative 
strategy targeting solid or hematopoietic malignant disorders over the last 
decade(Kelly et al., 2005; Glauben R. et al., 2009). They repress the pro-
inflammatory cytokines which can lead to apoptosis (Glauben R. et al., 2006). 
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Molecular mechanism of HDAC inhibitors in anticancer effects. Transcriptional 
repression in chromatin with HDAC can lead to cell growth and tumor growth; transcriptional 
activation in chromatin with HAT can lead to cell growth arrest, differentiation and/or 
apoptosis and inhibition of tumor growth. HDAC inhibitor can directly inhibit HDAC and 
indirectly activate HAT (Bi et al., 2006). 
 
 
There are many evidences which indicate that histone hypo-acetylation causes 
repression of tumor suppressor gene expression. Small molecular inhibitors of HDAC 
(HDACI) are very efficient in up-regulating the gene expression of tumor suppressor, 
resulting in tumor growth reduction and inducing programmed cell death (Liu et al., 
2006). 
Repressing HDAC activity and preventing the deacetylation of histone may result in 
hyperacetylation of histone, then unfolding the chromatin and promoting transcription 
factors to bind  to DNA and in this manner, genes which are inhibited can be 
expressed (Brown et al., 2002). HDAC enzymes eliminate the acetyl group from the 
histone (hypoacetylation), thereby decline the space between the nucleosome and 
the DNA wrapped around it, reducing transcription factor access and inducing 
transcriptional repression (De Ruijter et al., 2003; Bi et al., 2006). 
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 2.6 Protein stability 
 
Intracellular proteins are turning over extensively, this process is specific, and the 
stability of many proteins is controlled induvidually and can change under various 
conditions. Proteolysis of cellular proteins is a temporally regulated and tightly 
controlled process which plays major roles in broad array of basic pathways. Among 
these processes are cell cycle, development, differentiation, regulation of 
transcription, antigen presentation, signal transduction, receptor-mediated 
endocytosis, quality control, and regulation of different metabolic pathways. The 
stability of all cellulare proteins can be influenced by alteration in pathophysiological 
conditions, such as starvation or re-supplementation of nutrients (Aaron Ciechanover, 
2007). 
 
 
2.6.1 Protein degradation 
 
In eukaryotic cells the ubiquitin–proteasome and autophagy–lysosome pathways are 
the two main routes of protein and organelle clearance. Short-lived nuclear and 
cytosolic proteins are mainly degraded by proteasomes which are barrel-shaped 
multiprotein complexes (Ciechanover, A. 2006; David C. Rubinsztein 2006).  
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Schematic diagram of the ubiquitin–proteasome system. Before they are targeted for 
proteasomal degradation, most proteins are covalently modified with ubiquitin (Ub). Typically, 
three enzyme types are involved in this process — ubiquitin-activating (E1), ubiquitin-
conjugating (E2) and ubiquitin ligase (E3) enzymes. Proteins tagged with chains of four or 
more ubiquitins are shuttled to the the proteasome by various proteins such as CDC48/p97. 
In the proteasome, proteins are reduced to peptides, which are then released into the cytosol 
and further broken down by peptidases (David C. Rubinsztein 2006). 
 
Most proteins are targeted for proteasomal degradation after being covalently 
moderated with ubiquitin, which is conjugated through its carboxy terminus, usually to 
lysine residues. Three different kinds of enzymes involve in this conjugation: E1 is an 
ubiquitin activating enzyme. Hydrolyses ATP and makes a thioester-linked conjugate 
between itself and ubiquitin.; E2 which is an ubiquitin-conjugating enzyme forms a 
similar thioester intermediate with ubiquitin receiving it from E1; and E3 as ubiquitin 
ligase transfers the ubiquitin to the substrate binding both E2 and the substrate 
(Richly H. et al., 2005; Weihl et al., 2006;  Rubinsztein DC. 2006). 
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 Transcription can be influenced by Ubiquitin conjugation through different 
mechanisms (Muratani et al., 2003). Many transcription factors are ubiquitinated and 
degraded by the proteasome. In fact, in many cases,. , transcriptional activation 
domains and signals for Ubiquitin conjugation directly overlap. Ubiquitination and 
proteolysis of repressors even may stimulate transcriptional activity and reset a 
promoter for further rounds of transcription (Lipford et al., 2005; H.Lecker et al. 2006). 
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 Aims of the project 
 
Considering the fact that EAPP interacts with different proteins playing important 
roles in the cell cycle (Ludwig Schwartzmayer unpublished data), different EAPP 
truncations should be examined for interactions and post-translational modifications 
to identify the regulatory domains of this protein. 
 
Recognition of the sumoylation and acetylation sites of EAPP was planned based on 
the unpublished data of Peter Andorfer demonstrating the fact of post-translational 
modifications of EAPP. 
 
Identification of the protein domain playing a role in the stability of EAPP was also 
among the questions to be answered.  
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 3. RESULTS 
 
3.1. Generation of U2OS cells stably expressing EAPP truncations 
Considering the fact that EAPP interacts with different proteins playing important 
roles in the cell cycle (Ludwig Schwartzmayer unpublished data), this experiment was 
done with the aim of revealing the binding site of interacting proteins with EAPP. 
   
 
 
Transfection of the cells with the 
vector carrying the sequence  
  
 
 
Cloning of different EAPP 
truncations in a vector 
Selection with Geneticin 
Studying the activity of 
truncations compared to the wild 
type 
Isolation of single clones 
  
 
 
Fig.3.1.1. Different EAPP truncations were cloned in a vector. Then the U2OS cells were transfected 
with the vector carrying the sequence. The single clones were isolated after selection with geneticin 
and western blotting was performed with the cell lysate to study the activity of the truncations.  
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M    1    2     3    4     5    6     7   8    9    10   11 
1. U2OS 
2. HA-EAPP 
3. 1-120 
4. 1-140 
5. 1-160 
6. 1-180 
7. 1-240 
8. 1-266 
9. 55-C 
10 .95-C 
11. 135-C 
 
Fig.3.1.2: Western blot with α HA, the stably expressed levels of different EAPP truncations (as shown in the 
box) were studied in this figure. All the truncations have a HA tag and the expression could be followed by anti HA 
antibody in western blot. U2OS were loaded as a negative control.  
 
All the EAPP truncations were stably expressed, confirming the expected weight and 
size.   
 
  M  1   2   3    4   5    6    7   8    9  10  11  12  13  14 
1. U2OS 
2. HA-EAPP 
3. 1-120 
4. 1-140 
5. 1-160 
6. 1-180 
7. 1-240 
8. 1-266 
9. 55-C 
10 .95-C 
11. 135-C 
12.175-C 
13. 195-C 
14. 215-C 
 
Fig.3.1.3. 1E4 western blot, a western blot was performed with anti EAPP by EAPP truncations as shown in 
the box to study the expression of endogenous EAPP. 
 
As it can be seen, 1E4 antibody recognized the truncations 1-180, 55-C, 95-C and 
135-C indicating that the recognition site of 1E4 is between135-180. 
The protein amounts were higher in truncations 1-180, 55-C and 95-C compared to 
endogenous EAPP. 
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 3.2 Effect of drugs influencing cell cycle on EAPP truncations 
The fact of post translational modification and among that, putative sumoylation of 
EAPP (Peter Andorfer unpublished data), brought up the idea of finding these 
sumoylation sites on EAPP. The U2OS cells, stably expressing different EAPP 
truncations, were treated with Iodoacetamide which is the inhibitor of isopeptidases  
uestion was whether the truncations are differentially 
ffected by different drugs. 
     
that remove sumo moieties from the protein. 
They were also treated with TSA which is a histon deacetylase inhibitor and also with 
Etoposide, which inhibits topoisomerase II and leads to DNA double strand break. 
With this experiment the q
a
 
             
ugs. On the right, the ponceau stain belonging to  
is blot is shown.  
 the protein   
f protein after treatment with TSA.  
 
Fig.3.2.1 α-HA Western blot, a western blot was performed  
with anti HA, by EAPP truncations tagged with HA and treated with  
different drugs, as shown in the box, to examine if they are differentially  
1. U2OS WT 
2. U2OS+etoposide 
3. U2OS+TSA 
4. U2OS+iodoacetamide
affected by these dr
th
 
l 
 
amide 
1. 1-120+TSA 
2. 1-120+iodoacetamide 
 
5. HA EAPP norma
6. HA EAPP+etoposide 
7. HA EAPP+TSA
8. HA EAPP+iodoacet
9. 1-120 normal 
10. 1-120+etoposide 
1
1
 
 
Comparing the signal strength with
amount shown in ponceau stain,  
EAPP 1-120 showed higher levels  
o
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Fig.3.2.2 α-HA Western blot a western blot was performed  
with anti HA, by EAPP truncations tagged with HA and treated with different  
1. 1-140 normal 
2. 1-140+etoposide 
3. 1-140+TSA 
4. 1-140+iodoacetamide 
5. 1-160 normal 
6. 1-160+etoposide 
7. 1-160+TSA 
8. 1-160+iodoacetamide 
9. 1-180 normal 
10. 1-180+etoposide 
11. 1-180+TSA 
12. 1-180+iodoacetamide 
drugs, as shown in the box, to examine if they are differentially affected  
by these drugs. On the right, the ponceau stain belonging to this  
blot is shown.  
 
  
 
 
Fig.3.2.3 α-HA Western blot a western blot was performed  
with anti HA, by EAPP truncations tagged with HA and treated with different  1. 1-240 normal 
2. 1-240+etoposide 
3. 1-240+TSA 
4. 1-240+iodoacetamide 
5. 1-266 normal 
6. 1-266+etoposide 
7. 1-266+TSA 
8. 1-266+iodoacetamide 
9. 55-C normal 
10. 55-C+etoposide 
11. 55-C+TSA 
12. 55-C+iodoacetamide 
drugs, as shown in the box, to examine if they are differentially  affected  
by these drugs. On the right, the ponceau stain belonging to this  
blot is shown.  
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 Comparing the results of this part, higher protein amounts of some truncations (1-
120, 1-140, 1-160) were distinguished after treatment with TSA but this effect was not 
observed with other truncations.  
This difference in protein amount can either depend on levels of protein translation 
and mRNA transcrioption or might depend on stability of the protein at this part. 
 
 
 
 
3.3 Inhibition of gene expression in translational level 
 
Comparing the results of part 3.2, higher protein amounts of some truncations (1-120, 
1-140, 1-160) were seen after treatment with TSA. To examine if this difference 
depends on protein translation, the cells expressing full length and truncated  EAPP, 
were treated with Cycloheximide which is an inhibitor of protein biosynthesis in 
eukaryotic cells.  
Increased levels of protein amount can result from either higher expression or higher 
stability of the protein. 
This experiment was performed to examine the main cause of increased level of 
protein.  
If the induction by TSA occurs after translation then no expression was expected 
after treatment with cycloheximide. If the protein amount is maintained by TSA in the 
presence of cycloheximid, it indicates that TSA increases protein stability.  
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  1           2           3            4 
    1       2       3       4       
1. HA EAPP normal 
2. HA EAPP+TSA 
3. HA EAPP+cycloheximide 
4. HA EAPP+TSA+cycloheximide 
 
 
 
 
   1           2           3           4  1         2        3      4  
 
 
      3       4 
1. 1-120 normal 
2. 1-120+TSA 
3. 1-120+cycloheximide 
4. 1-120+TSA+cycloheximide  
 
   1           2            3           4                1        2      3      4 
1. 1-140normal 
2. 1-140+TSA 
3. 1-140+cycloheximide 
4.1-140+TSA+cycloheximide 
 
  
 
 
 
 
1. 1-160 normal 
2. 1-160+TSA 
3. 1-160+cycloheximide 
4.1-160+TSA+cycloheximide
   1           2            3           4                1        2      3      4 
 
 
 
 
Fig.3.3.1, α-HA Western blot                Fig.3.3.2, α βActin Western blot 
 
Fig.3.3.1 A,B,C & D; western blot was performed with anti HA, by full length and truncated EAPP tagged  with HA 
and treated with cycloheximide and TSA, as shown in the boxes.  
Fig.3.3.2 A,B,C & D; western blot with anti beta Actin, as loading control. 
 
  
 
As it can be seen in (Fig.3.3.1 B and D) the protein amount of EAPP1-120 and EAPP 
1-160 were both decreased after treatment with Cycloheximide; Treatment with TSA 
in the presence of Cycloheximid even did not affect the maintaining of protein 
amount.  
 
Full length EAPP together with EAPP1-140 (Fig.3.3.1 A and C) showed less 
decrease in protein amount as they were treated with Cycloheximid and surprisingly 
even higher levels of protein amount were observed when they were treated with 
both Cycloheximide and TSA which in turn can indicate that TSA-induced acetylation, 
accompanied with increased protein amount, can increase the  protein stability. 
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3.4 Cell cycle analysis with flow cytometry 
 
To examine the effects of EAPP on cell cycle, a flow cytometry was performed on 
U2OS cells with over expressed EAPP, Knocked down EAPP and the cells 
expressing truncation of EAPP, 1-140. The cells were pre-treated with Nocodazole to 
be arrested at G2/M phase and were then released by different time intervals. 
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Varying the amounts of full length EAPP within the range of our experiments had no 
effect on cell cycle because no difference was observed in cell cycle profile by 
Fig.3.4.2 which shows the effects of over expressed EAPP and Fig.3.4.3 which 
shows the effects of knocked down EAPP. Controversially the truncated EAPP, 1-
140, showed that the cells come out from M phase, slower than full length EAPP after 
release. 
 
 
3.5. Effect of EAPP 1-140 on cell cycle  
 
Flow cytometry was performed with the cells expressing EAPP 1-140 because the 
TSA effect was more pronounced by this truncation. The cells were pre-treated with 
nocodazole to arrest them in G2/M phase. Then they were treated once with and 
once without TSA by different time intervals after release. This experiment was done 
to examine if this truncation does affect the cell cycle in M phase and to see if this 
effect changes after release when they are treated with TSA. 
 
  
 
 
 
 
 
      Fig.3.5.1A; 1-140 Log 
                                                  Fig.3.5.1.B; 1-140 with nocodazole treatment overnight 
 
 
 
 
 
 
 
 
        
Fig.3.5.2.A; 1-140 w/o TSA 1.5h after release          Fig.3.5.3.A; 1-140 w/o TSA 3h after release 
Fig.3.5.2B; 1-140 with TSA 1.5h after release          Fig.3.5.3B; 1-140 with TSA 3h after release  
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Fig.3.5.4.A; 1-140 w/o TSA 4.5h after release          Fig.3.5.5.A; 1-140 w/o TSA 6h after release   
Fig.3.5.4B; 1-140 with TSA 4.5h after release          Fig.3.5.5B; 1-140 with TSA 6h after release 
 
 
 
1 2 3 4 5 6 7 8 9 10 
 
1. 1-140 normal 
2. 1-140 + noco 
3. 1-140 – TSA 1.5h 
4. 1-140 – TSA  3h 
5. 1-140 – TSA  4.5h 
6. 1-140 – TSA  6h 
7. 1-140 + TSA  1.5h 
8. 1-140 + TSA  3h 
9. 1-140 + TSA  4.5h 
10. 1-140 + TSA  6h  
 
 
 
1 2 3 4 5 6 7 8 9 10 
 
 
 
 
1 2 3 4 5 6 7 8 9 10
 
 
Fig 3.5.6 A, αHA Western blot; Western blot was performed with each of the FACS samples to check 
the levels of protein amount. They were tagged with HA and the loading map is shown in the box. 
Fig.3.5.6B, α  β Actin Western blot; western blot with anti beta actin as loading control. 
Fig.3.5.6 C, 1E4 (α EAPP); western blot with anti EAPP to check the levels of endogenous EAPP 
 
Generally the truncation EAPP 1-140 took much longer to re-enter the cell cycle after 
the release from Nocodazole. 
With a small difference, the cells without TSA treatment, shifted to S phase more 
than the TSA treated cells, in the first 1.5h and the last 6h after release. 
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Comparing the western blot analyses, the cells with and without TSA treatment 
showed the same protein amount after release (Fig.3.5.6A) but regarding the 
endogenous EAPP (Fig 3.5.6C) the cells showed less protein, the longer the intervals 
were after release and no strong difference was observed between the cells with and 
without TSA treatment.  
 
3.6. Protein stability and protein degradation 
After obtaining no adequate results to realize the reason for increased amount of 
expression by some TSA treated EAPP truncations (1-120, 1-140 and 1-160), it was 
thought that maybe the acetylation of EAPP has some effect on protein stability and 
not necessarily the protein biosynthesis results in increased levels of expression. 
Therefore the next step was to check the protein stability with “pulse chase” method.  
The truncation 1-140 by which the effects of treatment with TSA was more 
pronounced, together with other truncation of EAPP which covers the C terminal of 
the protein, 55-C and also the full length HA-EAPP were put through this method. 
Each of the samples was treated with and without TSA. Stability of all forms was 
evaluated by labelling for 30 min with [35S]methionine/cysteine-containing medium 
and a subsequent chase with medium containing non-radioactive methionine and 
cysteine.(Klenk et. al. 2006) The time intervals for harvesting were 5min, 1h and 3h 
after “chase” phase. 
 
 
 
        
  
 
 
 
  
 
 
1 2 3 4 5 6
1        2         3        4        5        6 
1 2 3 4 5 6
1.55-C – TSA 5min                    4.55-C + TSA 5min   
2.55-C – TSA 1h                        5.55-C + TSA 1h  
3.55-C – TSA 3h                        6.55-C + TSA 3h 
1.1-140 – TSA 5min                     4.1-140 + TSA 5min   
2.1-140 – TSA 1h                         5.1-140 + TSA 1h  
3.1-140 – TSA 3h                         6.1-140 + TSA 3h 
1.HA EAPP – TSA 5min               4.HA EAPP + TSA 5min   
2.HA EAPP – TSA 1h                   5.HA EAPP + TSA 1h  
3.HA EAPP – TSA 3h                   6.HA EAPP + TSA 3h 
Fig.3.6.1 A,B & C; full length EAPP and truncated EAPP treated with and without TSA, harvested by 
different time intervals of 5 min, 1h and 3h after chase phase. Western blot was performed with αHA. 
The loading map is shown in the box. 
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As it is shown in Fig. 3.6.1C, it seems that the C terminus of the protein (55-C) is less 
stable than the N terminal, where 1-140 belongs. Generally the protein had shown a 
longer half life when it was treated with TSA indicating that acetylation regulates its 
stability. Amazingly the truncation 1-140 showed the most stability.  
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 4. DISCUSSION 
 
4.1. U2OS cells stably expressing EAPP truncations 
 
4.1.1 Western blot analysis 
 
The production of cells, expressing different EAPP truncations, as it was explained in 
chapter 3.1, worked properly and the results shown Fig.3.1.2 did confirm our 
anticipation, considering the weight and size of each truncation. 
As it can be seen in Fig.3.1.3, the antibody 1E4 recognizes EAPP at the truncations 
1-180, 55-C, 95-C and 135-C confirming that the recognition site of 1E4 should be 
between135-180. 
 
4.2 Post translational modification of EAPP  
 
As it can be seen in figures of part 3.2, some of TSA treated EAPP truncations 
showed higher levels of expression. Trichostatin A (TSA) is a well-characterized 
histone deacetylase (HDAC) inhibitor. TSA is known to modify the balance between 
histone acetyltransferase and HDAC activities that induce histone hyperacetylation 
and regulate gene expression (Sung-Hye Kim et al. 2010). HDACs class I and class 
II, are TSA-sensitive and form a multiprotein repressor complex to remove the acetyl 
group from lysine residues of histones (Yang XJ et al. 2007). Recently, the effect of 
TSA in acetylation/ deacetylation of nonhistone proteins has been demonstrated as a 
diverse regulatory event, including ubiquitination/proteasomal degradation. (Sung-
Hye Kim et al. 2010).  
Regarding Fig.3.2.1 and 3.2.2, two truncations, 1-120 and 1-140 appeared to have 
increased level of expression in comparison to other truncations. It can somehow 
depend on the clonal effect and that the inserts do not always integrate in the same 
site of DNA. The problem can be solved by Flip in system by which the insert and the 
host DNA have two flanking sites on a definite part, which could be recognized by 
integration.  
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On the other hand it can also depend on amount of protein translation or may rely on 
protein stability which were examined in the subsequent experiments. 
 
4.3 Inhibition of gene expression in translational level 
 
Treatment with Cycloheximide inhibits the protein biosynthesis in the cell. Referring 
to Fig.3.3.1, effects of treatment was observed with EAPP 1-120 and 1-160 but 
surprisingly not with EAPP 1-140 and full length EAPP, although it was supposed to 
maintain no expression, if the induction by TSA occurs after translation. 
  
On the other hand, the protein amount of EAPP 1-140 and full length EAPP in the 
presence of Cycloheximide was maintained by addition of TSA, observing higher 
amount of protein. Therefore it can be concluded that Trichostatin A increases 
acetylation and protein stability at this part of EAPP. 
 
 
 
 
1 2 3 4 1 2 3 4
                               
        
 
           
1. 1-140normal 
2. 1-140+TSA 
3. 1-140+cycloheximide 
4.1-140+TSA+cycloheximide 
 
 
1. HA EAPP normal 
2. HA EAPP+TSA 
3. HA EAPP+cycloheximide 
4. HA EAPP+TSA+cycloheximide 
 
1A and 1C; western blot was performed with anti HA, by full length EAPP and 1-140, tagged  with HA and treated 
with cycloheximide and TSA, as shown in the boxes. 
2A and 2C; western blot with anti beta Actin, as loading control. 
 
 
With truncation EAPP 1-140, TSA effect appeared to depend on stability of the 
protein at this part but still could also be influenced by transcription. 
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4.5 Effect of EAPP on cell cycle profile 
4.5.1 FACS Analysis 
 
It was proved that there are more cells in S-phase if EAPP is over-expressed. On the 
other hand, EAPP knock down by RNAi, reduces the fraction of cells in S-phase 
dramatically (Novy et al., 2005). Another result suggests that cells overexpressing 
EAPP abrogate nocodazole -induced arrest (Peter Andorfer, unpublished data). 
 
In the DNA profile analyses in FACS experiments, however there was no difference 
shown between cells that had an EAPP knockdown and cells with an EAPP 
overexpression. This in turn could depend on the density of the cells, as it is indirectly 
proportional to the cell number in S-phase. The denser they are, the fewer cells are in 
S phase. 
Contradicting P.Andorfer’s result, the cells overexpressing EAPP, do undergo 
Nocodazole arrest. 
 
U2OS cells expressing EAPP 1-140 took much longer than control cells or cells over-
expressing full length EAPP to re-enter the cell cycle after the release from 
Nocodazole, It may be due to a clonal effect or may be exposure to stress through 
treatment with Nocodazole, has been highlighted in this part of protein or maybe 1-
140 has interplay with mitotic control proteins which undergo depletion after arrest.  
 
4.6 Effect of 1-140 on cell cycle 
4.6.1 FACS analysis 
 
Generally the truncation EAPP 1-140 took much longer to re-enter the cell cycle after 
the release from Nocodazole. 
With a small difference, the cells without TSA treatment, shifted to S phase more 
than the TSA treated cells, in the first 1.5h and the last 6h after release.  
This truncation of EAPP might have some effects on inhibition of cyclin-dependent 
kinase (CDK) complexes. CDK complexes regulate transitions between different 
phases of the cell cycle. (Bey-Dih Chang et al, 2000).  Consequences of CDK 
inhibition include dephosphorylation of pRb and downregulation of a large group of 
E2F-dependent genes that are involved in DNA replication and cell cycle progression 
(Nevins, 1998). 
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Considering the DNA profile of TSA treated cells, acetylation of this truncation seems 
to have stronger effects on inhibition of mitotic control proteins.  
4.6.2 Western blot analysis 
 
Considering the western blot analyses with anti HA in Fig.3.5.6A, treatment with TSA 
in different time intervals after release, didn’t affect the protein amount of EAPP.  
Interestingly the amount of endogenous EAPP was descending over the time after 
release. Regarding the endogenous EAPP levels, a tiny difference was recognized 
with TSA treated cells.  
 
4.7 Protein stability and degradation 
4.7.1 Analysis with pulse chase 
 
It seems that EAPP proteins with a deleted N-terminus (55-C) is less stable than the 
part containing this part (1-140). Generally the protein had shown more stability as it 
was treated with TSA compared to without TSA.  
This result indicates the TSA affected protein stability at the N terminus. Referring to 
chapter.3.3, the protein level of 1-140 was sustained by TSA in the presence of 
Cycloheximide, indicating that TSA increases the protein stability of this truncation. 
It seems that Trichostatin A enhances acetylation as well as the stability of the 
protein but the precise mechanism remains unclear (Sung-Hye Kim et al. 2010).  
Amazingly the truncation 1-140 showed the most stability in comparison to full length 
EAPP and 55-C. 
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 5. Material and Methods 
 
5.1 Cell lines: 
 
U2OS (ATCC: HTB-96): Human osteosarcoma cell line. The cells were grown in  
DMEM with 10% FCS and AB. 
T98G (ATCC: CRL 1690): Human glioblastoma cell line. The cells were grown in 
DMEM with 10% FCS and AB. 
 
 
5.2 Vectors: 
 
pCIneo-HA-MCS: Expression vector with a Hemaglutinin-tag and a multiple cloning 
site 
pSuper: RNAi vector based on the pBlueScript-KS vector with ampicilline resistance  
 
5.3 Special chemicals, antibodies and solutions 
ECL detection solution 
Reagents: 
p-Coumaric acid Sigma 
3-Aminophtalhydrazide (Luminol) Fluka 
Hydrogen Peroxide 30% Aldrich 
Nitrocellulose Transfer Membrane Protran 
PEI 25000  Aldrich 
Protein-Assay Dye Reagent BIO-RAD Protein Assay 
Silica Sigma 
X-Ray Films Fuji Medical X-Ray Film 
Antibodies: 
α-EAPP polyclonal Mouse polyclonal 
α-EAPP [1E4] Mouse monoclonal 
α-EAPP [4A6] Mouse monoclonal 
α-HA [16B12] Babco 
α-β-Actin 
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αP53 Santa Cruz 
 
 
5.4 Solutions 
 
40% Acrylamid (100ml H2O):  
    
38 g Acrylamid 
2 g NN´Methylenbisacrylamid 
add one spoon DOWEX-
Ionenaustauscherharz.  
Store at 4°C in the dark 
Antibiotics: 1000 x Ampicillin (50 mg / ml) 
1000 x Kanamycin (50 mg / ml) 
 
Blocking Solution for primary ab´s:  1 x PBS  
0,1 % Tween  
Sodium Azide (20 % NaN3 = 20000 
stock) 
3 % Milkpowder 
Blocking Solution for secondary ab´s 1 x PBS 
0,1% Thinerazol 
0,5% Milkpowder 
Coomassie blue:              0,25 % (w/v) Coomassie R 
10 %  (v/v) Aceticacid   
50 %  (v/v) Methanol 
Filtration 
Destaining Solution:  10% Acetic acid 
30% MeOH 
60% distilled H2O 
DNA-Loading dye:    0,25 % Bromphenolblau (25 mg) 
0,25 % Xylen-Cyanin  (25 mg) 
30 % v/v Glyzerin 
x  ml H2O to 10 ml 
1000x Ethidium bromide:   5 mg Ethidium bromide / ml H2O 
Hunt extraction buffer 20 mM TRIS/HCL pH=8,0 
100 mM NaCl 
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1 mM EDTA 
0,5 % NP-40 
1 mM DTT 
1 mM PMSF 
Laemmli sample buffer:   
    
 
100 mM TRIS-HCl pH=6,8 
20 % Glycerol 
0,01 % Bromphenolblue 
10 % ß-Mercaptoethanol 
5 % SDS 
10 x PBS: 80 g / l  NaCl 
2 g / l KCl 
2 g / l Kaliumdihydrogenphosphate 
11,5 g / l Disodiumhydrogenphosphate 
pH= 7,4 
Ponceau:  0,2 % w/v Ponceau S   in 3 % 
Trichloracetic acid 
10x Running buffer:  
    
192mM Glycin 
25mM TRIS 
0,1 % SDS 
Stripping buffer:   100mM   2-Mercaptoethanol 
2 % (w/v) SDS 
62,5mM TRIS-HCl pH 6,7 
1x TE: 10mM TRIS/Cl 
1mM EDTA 
pH= 8.0 
5 x Transfer-buffer (2000 ml):   125mM TRIS...........30,29 g 
960mM Glycin...144,13 g 
For 1 x Buffer add 20 % v/v Methanol 
prior of use.  
UltraNewWash: 
 
50mM NaCl 
10mM TRIS/HCl pH=7,5 
25mM EDTA 
50 % v/v Ethanol 
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5.5 SDS-PAGE Minigel 
 
 6 % 8 % 10 % 12 % 14 % Stacking 
40 % 
Acrylamid 
600 µl 800 µl 1 ml 1,2 ml 1,4 ml 250 µl 
ddH2O 1,85 ml 1,65 ml 1,45 ml 1,25 ml 1,05 ml 1,48 ml 
1 M TRIS-Cl, 
pH= 8,7 
1,5 ml 1,5 ml 1,5 ml 1,5 ml 1,5 ml 250 µl 
20 % SDS 20 µl 20 µl 20 µl 20 µl 20 µl 10 µl 
TEMED 4 µl 4 µl 4 µl 4 µl 4 µl 2 µl 
10 % APS 20 µl 20 µl 20 µl 20 µl 20 µl 10 µl 
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 6. EXPERIMENTAL METHODS 
 
6.1 Bacterial Cultures 
 
6.1.1 Luria Broth (LB) 
 
1% Trypton, 1% NaCl, 0,5% Yeast-extract, (1,5% Agar-Agar for plates) 
LB has to be sterilized by autoclavation 
 
6.1.2 For Agar Dishes 
 
1% Trypton 
1% NaCl 
0,5% Yeast extract 
1,5% Agar 
The Antibiotics (Ampiciline/Tetracycline) were supplied after cooling down the 
autoclaved agar to 50°C 
Pour out the solution into petri-dishes 
 
6.1.3 Storage of bacteria 
 
0,9 ml of an overnight culture were added to the same volume of freezing buffer and 
stored at –80°C 
2x Freezing buffer:  
12.6g/l    K2HPO4     
  3.6g/l    KH2PO4   
 0.9g/l    Na-Citrat    
 1.8g/l    (NH4)2SO4     
0.18g/l    MgSO4 .7H2O   
88.0g/l    Glycerol 
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6.1.4 Transformation of competent E.coli 
Mix DNA and an aliquot of competent cells.  
Keep the mixture 20min on ice 
Heat shock the cells 2 min at 42°C.  
Add 400µl LB and keep the cells on 37°C for 30min.  
Plate the suspension on antibiotic-plates. 
 
6.2 Mammalian cells 
 
6.2.1 Media for mammalian cell 
 
DMEM (10 Litre): 
„Dulbeco´s modified Eagles´s Medium“ [Gibco / BRL # 52100 /039] powder solved in 
5 Litre Aqua. dest. Addition of 30g NaHCO3. Addition of 5 Litre aqua. dest.  
Sterilfiltration [ Satorius P plus]. Immediately before use ad 10 % FCS (foetal calf 
serum) or 10 % CS (Calf serum) and AB or AB+G. 
100 x antibiotic-stock (AB): 
6g/l Penicillin G, Potassium salt, 10g/l Streptomycinsulfate. Antibiotics are solved in 
1x PBS and sterile filtrated [0,2µm]. 
50 x AB+G in 1x PBS: 
5,8 g / l Glutamat, 6 g/l Penicillin G, Pothassium salt, 10 g/l Streptomycinsulfat.  
AB+G are solved in 1x PBS and sterile filtrated [0,2µm]. 
Trypsin/EDTA Solution: 
500mg / 1000ml Trypsin 
0,2 w/v% NaEDTA 
solved in H2O and sterile filtrated [0,2µm]. 
 
6.2.2 Storage of mammalian cells 
 
Mix cells in media + 10 % v/v DMSO + 50 % v/v FCS. Freeze 2 hours at –20, then at 
– 80°C up to a view weeks, then in N2. 
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 6.2.3 Propagation and splitting of cells 
 
Attached cells were grown in petri-dishes at 37°C in special chambers with 
waterstream saturated atmosphere containing 7,5% CO2. For splitting confluent cells 
the petri-dish had to be washed once with warm 1xPBS and incubated with about 12 
drops T/E for 1-10 min. The floating cells were now resuspended in complete DMEM 
medium to stop the activity of T/E and were diluted to the preferred density. 
 
6-wells, 3 ml media per well (10% FCS or 10% CS) 
Ø 100 mm plate, 10 ml media (10% FCS or 10% CS) 
Ø 140 mm plate, 20 ml media (10% FCS or 10% CS) 
 
6.2.4 Transfection of mammalian cells (PEI –method) 
 
Ø 100 mm plate, 10 ml media (10 % FCS). Change media two hours prior to 
transfection and 24 hours after transfection. 
Transfection mix: 
x µg DNA in H2O 
ad 200µl 150mM HBS (steril) 
Add 200µl 150mM NaCl with PEI working solution (ratio DNA(µg) : PEI(µl) ~ 1:2,5) 
Vortex 10 sec and let mixture rest for 10 min 
Add to cells  
 
6-Wells  1-5 µg DNA and 200 µl HBS 
Ø 100 mm plate 10-20 µg DNA and 400 µl HBS 
Ø 140 mm plate 20-30 µg DNA and 1000 µl HBS 
2x HBS: 
280 mM NaCl 
50 mM HEPES 
1,5 mM Na2HPO4 
PEI working solution: 
42.2g PEI 25000 in 42.2g H2O 
Mix well for 4-5h 
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Use 87µl of this solution and add 100ml H2O  
Adjust pH to 7.0 with HCl 
Steril fitration, aliquote and store at 4°C 
 
6.2.5 Cell-extracts of mammalian cells 
 
Wash cells two times with 1x PBS. 
Resuspend the cell pellet in 5x volume HUNT-extraction buffer or 3x volume WCE-
extraction buffer.  
Freeze-thaw 2-3 times in liquid N2 
Centrifuge 10min with 14000rpm  
Store supernatant at -80°C  
 
 
HUNT-Extraction buffer: 
20 mM TRIS / HCl pH=8,0 
100 mM NaCl 
1 mM EDTA 
0,5 % NP-40 
1mM DTT 
1mM PMSF 
 
6.2.6 Protein Quantification (Bradford) 
 
For the quantification of proteins in extracts the method of Bradford was used. 
Therefore 1ml Bio-Rad Solution (1:5) was incubated with 3, 5 and 10 µl of the 
concentration standard BSA (1µg/µl) and 1-10µl of the sample extracts for 5-10 min. 
The specific extinction was analysed in a spectrophotometer at 595nm. With the 
known BSA concentrations a standard curve can be obtained and the protein 
concentration of the cell extracts can be determined by comparing the ODs. 
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6.3 Methods for DNA 
 
6.3.1 Plasmid DNA preparation 
 
6.3.1.1 over night culture 
 
Bacteria, picked directly from the petri dishes or taken from frozen cultures, were 
incubated in 2-6 ml LB-media with antibiotics and shaked over night at 37°C under 
aerobe conditions. These cultures can be used either for mini- or maxipreps, for 
protein expression experiments, of freezing.  
 
6.3.1.2 Small scale plasmid DNA preparation with silica milk 
(Miniprep) 
 
Harvest cells by centrifugating of bacteria culture in eppendorf tube 5min 14000rpm; 
RT 
Remove supernatant and resuspend pellet in 200µl Solution I plus 2µl of RNaseA 
(10mg/ml), 10min on ice  
Add 400µl of Solution II and shake, 10min on ice 
Add 300µl of Solution III and shake, 10min on ice 
Add 20-30µl of silica milk and incubate on a shaker for 10-20 min; 37°C, 900 rpm.  
Wash the silica-pellet 2 x with Ultra New Wash.  
Resuspend the pellet in 20-50 µl H2O and heat the probe 5 min 55°C.  
Transfer the supernatant into a fresh Eppendorf-tube. 
 
Silika milk: 
Wash silica two times with H2O 
Prepare a 50/50 Solution of silica and H2O 
Store at 4°C in the dark 
 
Solution 1: 50mM Glucose 
  25mM TRIS-HCl pH=8 
  10mM EDTA 
Solution 2: 0,2 N NaOH 
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  1 % SDS 
Solution 3: 3 M KOAc 
  5 M Acetic acid 
 
6.3.1.3 Large-scale plasmid DNA preparation: 
 
Harvest cells of a 500 ml bacteria-culture by centrifugation (5 min, 6000 rpm, 4°C). 
Resuspend the pellet in 20 ml cold Solution 2. Add a small aliquot Lysozym and 
shake . 
Add 40 ml Solution 2 and wait 10min, RT.  
Add 20 ml Solution 3 and wait 10min, RT. 
Centrifugation (20 min, 8000 rpm, 4°C). Filter the supernatant through a fine paper 
layer into 50ml isopropanol.  
Centrifugation (20 min, 10000 rpm, 4°C).  
Drain the pellet and resuspend in 5 ml TE. Transfer the solution into a clean SS34-
beaker and add 5 ml 5M LiCl.  
Centrifugation (20 min, 10000 rpm, 4°C). Transfer the supernatant into a clean SS34-
beaker and add 10 ml isopropanol. 
Centrifugation (20 min, 10000 rpm, 4°C). Drain the pellet and resuspend in 500 µl 
TE.  
Add 20 µl RNaseA (10 mg / ml), 30 min, RT.  
Add 500 µl 2 x PN and shake. Put the mixture 10min on ice. 
Centrifugation (10 min, 14000 rpm, 4°C). Resuspend the pellet in 400 µl TE.  
Add 10 µl RNaseA (10 mg / ml), 30 min, RT. 
 2 x extraction with 400µl phenol / chloroform / isoamylalkohol. 1 x Extraction with 
400µl chloroform. 
Precipitate the supernatant with 100µl 10M NH4OAc and 800 µl cold 96 % ethanol. 
Centrifugation (10 min, 14000 rpm, 4°C). Wash the pellet 2 x with 1ml 70 % ethanol. 
Dry pellet in speed-vac 
Resuspend the dry pellet in 400 µl TE.  
2 x PN:  30 % PEG 6000 
   1,5 M NaCl 
Lithiumchlorid: 5M LiCl 
Ammoniumacetat:  10M NH4OAc 
TE :   10mM TRIS-HCl pH=8 
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1mM EDTA pH=8 
 
 
6.3.2 DNA Purification 
 
6.3.2.1 DNA isolation from agarosegel with silica-milk: 
 
Melt agarose-DNA slices in 3x volume of 6M NaJ at 55°C, 600 rpm.  
Add 10-15µl silica suspension and incubate on a shaker for 10-20 min; 30°C, 600 
rpm.  
Wash the silica-pellet 2 x with Ultra New Wash.  
Resuspend the pellet in 30 µl TE and heat the probe 5 min 55°C.  
Transfer the supernatant into a fresh Eppendorf-tube. 
 
 
6.3.3 DNA Quantification 
 
To estimate the amount of DNA, separated DNA samples in the agarose gel were 
compared to the DNA markers of known concentrations under UV. 
For precise quantification y µl of DNA-solution (in TE) were diluted with water to 1 ml 
and measured in a photometer: µg/µl = OD260 x 50 x y (used µl of DNA) 
If OD260 us between 1,8 and 2,0 the DNA is clean, but less than 1,8 indicates for 
impurities in the solution 
 
 
6.4 Special methods 
6.4.1 Immunoblot analysis 
 
Samples: 
Mix 10-20 µg cell extract with an equal volume of Laemmli sample buffer and boil for 
3-5 minutes at 95°C 
Unused samples may be stored at –20°C 
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Electrophoresis: 
Load 2-3 µl protein marker per well and the samples 
Electrophorese in 1x Running buffer: 125mV 
 
Transfer to membrane: 
Transfer proteins from the gel to a nitrocellulose membrane 
Use an electroblotting apparatus 
 
Blotting: 
250mA for 2,5 hours at 4°C 
Use ice for cooling the transfer buffer 
 
Immunostaining: 
Block non-specific binding by incubating the membrane in a blocking solution for 30 
min at RT  
Incubate the blocker membrane for 1, 5 hours with primary antibody-milk 
Wash three times for 10 min in PBST 
Incubate the membrane for 1 hour with secondary antibody 
Wash three times for 10 min in PBST 
 
Detection of bound antibodies: 
Incubate the membrane for 1 min with ECL detection solution 
6.4.2 Fluorescence activated cell sorter (FACS) -Analysis 
 
Preparation of cells for FACS: 
Wash cells twice with PBS. Add Trypsin/EDTA. Incubate at 37°C.  
Stop the reaction by addition of 1ml media + 10% FCS.  
Centrifugate for 5min at 1000rpm, discard the supernatant.  
Add 1ml PBS and centrifugate (1000 rpm, 5min).  
Resuspend the pellet in 1mlPBS.  
Pour the necessary amount of suspension into 5ml cold 85% ethanol and store at –
20°C. 
 
Staining of cells for FACS: 
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Centrifugation of fixed cells (1000 rpm, 2min, 4°C). Remove supernatant and 
resuspend the 
pellet in 100-200µl 0,05% Pepsin (Sigma # P-7000). Add 1-2 ml staining solution 
(3min, RT). 
Store at 4°C and use the preparation for FACS-analysis in between the next two 
hours. 
Staining solution: 
100mM TRIS-HCl pH= 7,5 
2mM MgCl2 
0,1 % Triton-X 100 
2µg / ml DAPI (4,6-Diamidino-2-phenylindolhydrochlorid; Merck # 25653) 
15µg / ml Sulforhodamin 101 (Sigma #. S-7635) 
 
6.4.3 Nocodazole arrest and release 
 
Grow cells up to 80% confluency 
Add nocodazole and remove medium after 16h through centrifugation 
Wash cell pellet once with 1xPBS 
Resuspend cell pellet in new medium and add to the cells 
To harvest the cells, use the cell scraper 
 
 
6.4.4 Metabolic Labelling of Proteins and Immunoprecipitation 
(palse chase method) 
 
Cells were starved for 30 min in 1 ml of methionine/cysteine^and FCS free medium, 
then metabolically labeled for 30 min with 125 μCi/ml of 35S-methionin in 
methionine/cysteine-free medium (pulse), washed free of unbound radioactive amino 
acids, and incubated in prewarmed complete medium (chase). At the indicated time 
points, the cells were disrupted in ice-cold hunt lysis buffer and immunoprecipitated 
with anti-HA antibodies. Proteins were subjected to SDS-PAGE.  
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